Adverse Event Reporting Timelines: Federal Approach and Abu Dhabi DOH 5-Day and 15-Day Standards

1. Key takeaways

The UAE currently runs two parallel clocks for medical device adverse event reporting. On the emirate-level side, the Abu Dhabi Department of Health (DOH) Standard on Medical Device Reporting is a written standard: for death, serious injury, malfunction, and events for which remedial action must be taken to avoid a major risk to public health, the responsible party should report within 5 days of becoming aware; other device reports, such as use error, quality problems and treatment failure, are due no later than 15 days; where information is missing from the initial report, it should be completed within 1 month of receiving the request for supplementation. On the federal side, Article 21(6) only requires the rights holder to comply with the EDE vigilance guidance, and EDE has not yet published a unified federal timetable for device adverse events; the 48-hour / 10-day / 30-day three-tier scheme circulating in the industry is a practical estimate with no official regulatory source. Our handling principle: treat the DOH 5-day and 15-day deadlines as the hard external floor, and demote the 48-hour, 10-day and 30-day tiers to internal accelerated response targets, used only for internal management and never written into contracts or external commitment documents.

• Death, serious injury, malfunction and events requiring remedial action to avoid a major public health risk: report within 5 days of awareness under the DOH standard.
• Use error, quality problems, treatment failure and similar device reports: no later than 15 days.
• Missing information from an initial report: complete within 1 month of receiving the DOH request.
• The federal 48-hour / 10-day / 30-day scheme is a practical estimate only and must not appear in external commitments.

2. Legal basis

The two reporting regimes and their sources are set out in the table below, together with the federal provisions that anchor the reporting duty on the rights holder.

3. Expert insights

Insight 1: The DOH 5-day and 15-day tiers distinguish event severity, not reporting format. Our professional judgment is to classify first by the consequence of the event and then select the clock; the order cannot be reversed. The reason is that DOH places malfunction in the same tier as death and serious injury, which shows that as long as there is a possibility of a major risk to public health, the 5-day tier applies even if no personal injury has yet occurred. On the trade-off, do not switch to the 15-day tier merely because a third party has not yet confirmed causation, because the starting point of the 5-day clock is awareness, not confirmation, and waiting for confirmation is itself consuming the statutory deadline.

Insight 2: The federal 48-hour / 10-day / 30-day scheme is a practical estimate and cannot serve as the basis for external commitments. The judgment is that external contracts, standard operating procedures and written replies to EDE should cite only the DOH standard or the specific content of an EDE enquiry; the 48-hour, 10-day and 30-day tiers serve only as internal acceleration targets. The reason is that the Executive Regulation has not yet been issued in full; if a practical estimate is written into a commitment document, then once EDE later publishes formal timelines the company will face the double risk of breaching the contract and breaching the new regulation, and the former is usually asserted by the counterparty before the latter.

Insight 3: The 1-month supplementation period and the initial 5-day / 15-day periods run independently. The judgment is that the 1-month period exists only after the DOH request for supplementation has been received; it by no means allows the initial report to be dragged out to the full 5 days plus 1 month. The reason is that the starting point of the DOH supplementation period is receipt of the request. On the trade-off, the initial report should follow a strategy of reporting first even with incomplete information, because a delay in the initial report cannot be remedied by later supplementation.

4. Practical recommendations

• Build an event triage table and embed it in the case intake form: death, serious injury, malfunction and events requiring remedial action to avoid a major risk to public health go on the 5-day track; use error, quality problems and treatment failure go on the 15-day track.
• Record the starting point uniformly as the day any person in the company becomes aware; it does not start at confirmation of causation or at receipt of a physical sample.
• External documents cite only the 5-day and 15-day deadlines of the DOH Standard on Medical Device Reporting; the federal 48-hour / 10-day / 30-day scheme is labeled a practical estimate, serves only as an internal acceleration target, and is not written into contracts or commitment letters.
• Adopt a report-first-supplement-later approach for initial reports; complete missing information within 1 month of receiving the DOH request for supplementation, and retain the receipt records in full as evidence of the starting point.
• Run dual-track drills of the response chain between the responsible entity and the manufacturer’s internal team, covering UAE public holidays and staff changes at the responsible entity.
• Keep reports with an English master copy, and prepare an Arabic version where entities under the Abu Dhabi health authority are involved.

5. Verification checklist

• □ The event triage table has been issued, with written definitions of the criteria for the 5-day and 15-day tiers
• □ The starting-point rule has been set as the day of awareness and made a mandatory field in the case intake form
• □ No practical estimate formulations such as 48 hours / 10 days / 30 days appear in external contracts or commitment letters
• □ The initial report template can be submitted with incomplete information, with fields reserved for later supplementation
• □ Receipt records for DOH requests for supplementation are traceable and support the start of the 1-month supplementation period
• □ At least one dual-track response drill between the responsible entity and the manufacturer has been completed
• □ English master templates and Arabic version templates have both been archived and put into effect

Further reading: Article No. 41, Pharmacovigilance System Obligations: Article 6(b), Article 21 and Article 23; Article No. 44, Post-Market Surveillance Reporting and PSUR: The 70-Day and 90-Day Rules and the Two-Year Cycle; Article No. 32, The Local Authorised Representative (LAR) and the Authentication Chain of the Power of Attorney (POA).

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team manages adverse event reporting and recall coordination with MOHAP, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com